Session » Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 570

A Molecular Timeline for Preclinical RA Pathogenesis Defined By Dysregulated PTPN22, Hypercitrullination, and Aberrant Cytokine/Metabolic Profiles in PBMC of at-Risk Individuals

9:00AM-11:00AM: Abstract Number: 582

ACPA Induce Pathogenic Cytokines Expression in PBMC of ACPA+-RA Patients and Inhibition of Its Effect By Cit-ME a Synthetic Citrullinated Peptide

9:00AM-11:00AM: Abstract Number: 574

Anti-CCP3.1 and Anti-CCP3-IgA Antibodies Are Associated with Increasing Age in Subjects without Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 576

Anti-CCP3.1 and Anti-CCP3-IgA Are Elevated in RA-Free Subjects with Idiopathic Pulmonary Fibrosis

9:00AM-11:00AM: Abstract Number: 572

Anti-Periodontal Bacteria Antibody Titers Are Inversely Correlated with ACPA in RA-Free Individuals with Periodontal Disease Compared to Community Controls

9:00AM-11:00AM: Abstract Number: 586

Association Between ACPA Fine Specificity and High Resolution Computed Tomography Lung Changes in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 583

Associations of Serum Anti-Citrullinated Proteins and Cytokines with Radiographic Scores in African-American Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 581

Cell-Mediated Neutrophil Lysis-a Mechanism Promoting Hypercitrullination in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 575

Differences in Histological Scores and Histoclinical Correlations in ACPA- Versus ACPA+ Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 585

Disease Associated Anti-Citrullinated Protein Memory B Cells in Rheumatoid Arthritis Persist in DAS Remission

9:00AM-11:00AM: Abstract Number: 578

Do Specific Anti-Citrullinated Antibodies Predict Different Phenotype of Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 584

Glycoprotein VI: A Potential Target for ACPA-Mediated Platelet Activation?

9:00AM-11:00AM: Abstract Number: 571

High Titer Rheumatoid Arthritis Antibodies Distinguish Between PAD2 and PAD4 Citrullinated Fibrinogen

9:00AM-11:00AM: Abstract Number: 590

Microvesicles in the Lungs of Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 579

MRI-Detected Osteitis Is Not Associated with the Presence or Level of ACPA Alone, but with the Combined Presence of ACPA and RF

9:00AM-11:00AM: Abstract Number: 589

Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 580

Preferential Distribution of M1 Monocytes in Anti-Cyclic Citrullinated Peptide Antibody Positive Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 588

Radiographic Progression Is Less Significant in Anti-Carbamylated Antibody-Positive Patients with Rheumatoid Arthritis (RA) Who Were Clinically Active and Under the Treatment with Biological Dmards

9:00AM-11:00AM: Abstract Number: 573

Synovial Fibroblast-Neutrophil Interactions Promote Pathogenic Adaptive Immunity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 587

Synovial Immunophenotype and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiological Prognosis

9:00AM-11:00AM: Abstract Number: 577

TCZ Modulates the Production of Ccfdna Derived from RA Synovial Cells

9:00AM-11:00AM: Abstract Number: 568

Triggering Receptor Expressed on Myeloid Cells (TREM) As a Novel Indicator of Disease Progression in ‘at-Risk’ Individuals

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].